Oncolytics Biotech Inc T.ONC

New Press Release - Oncolytics Biotech® To Present Two Posters on the Pelareorep-Based GOBLET Study at ESMO 2023

Preliminary updated PDAC data show 6-month overall survival rate of 82%Results from pelareorep combination in mCRC met the Stage 1 success criteriaSAN DIEGO and CALGARY, AB, Oct. 16, 2023/PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics...read article.

[itntdf]

and this is the challenge when pela is used as a rescue or third-line type of therapy. from the press release:The authors believe that protective immune responses were initiated in these patients but that they may have been too immunocompromised or have insufficient time before disease progression to fully benefit from the pelareorep-based immunotherapy. when it takes 9 months to "bloom

[Lesalpes29]

And difficult to evaluate the real value of the product. An other 12 months probably needed if the BP in play want to see more results? GL

[Azzak34]

Nope. This is 1 trial in later stages of disease after the patients have been beat up already by other treatment. We are going to be a 1st line treatment!!!  Please folks, when we give opinions can we make sure we know what's going on? 

[Azzak34]

Capitalista..... these are from the cutoff, updated results will be presented at ESMO.  1st line results are brilliant and will only get more brilliant in next week's update. 

[Capitalista]

Thanks, Azzak.  I wonder why ESMO has a 10-month cutoff - this seems extreme.  One would think biotech firms would find more timely ways of presenting their results than this, if only to avoid the news drought we seem to have been going through.  I certainly hope we will get updated numbers shortly.  Or something like a business development or announcement of the successful

[newcoin]

This is what it's all about. Exciting!!

[Capitalista]

Am I missing something here?  The data cutoff for ESMO is listed as 19 Jan 2023 - ten months before the conference.  These data are only mildly more recent than those reported at SITC 2022 (where the cutoff was 12 Oct 2022).  The ESMO conference is  11 months later; surely we can get more recent results? If anyone can speak to this, please do so.

[Noteable]

As of the data cutoff date of July 28, 2022, 7 evaluable patients of 10 who were enrolled in the PDAC cohort of the GOBLET trial achieved a partial response, including 3 confirmed and 4 unconfirmed. Two more patients achieved stable disease for an ORR of 70% and a CBR of 90%, respectively. These ORR data are nearly triple the average ORR which have been reported in historical control trials

[Noteable]

As of the data cut-off (January 19, 2023), the median duration of response (mDOR) was 6.0 months, the 6-month progression-free survival (PFS) rate was 72.9%, and the 6-month overall survival (OS) rate was 82.1%.  Updated data from the study reported in the October 2023 ESMO abstract showed that 8 of 13 evaluable patients had a partial response (PR

[jh1970]

Why market is in red if this is so good ? 

[jh1970]

"Updated efficacy and TCR-seq results will be presented at ESMO; final PFS and OS are pending." So today we got already updated results or not ?

[Noteable]

10 evaluable patients in October 2022 vs 13 evaluable patients with median durable responses (mDOR) and overall survival (OS) rates being reported in October 2023 is certainly an update from the previous report.

[Noteable]

The survival statistics for newly diagnosed advanced/metastatic pancreatic cancer patients is grim - as only 10% of newly diagnosed advanced/metastatic cancer patients survive beyond 1 year 

[Noteable]

These ORR data are nearly triple the average ORR which have been reported in historical control trials, suggesting that pelareorep synergizes with PD-L1 inhibitors and standard-of-care chemotherapy in patients with advanced/metastatic pancreatic ductal adenocarcinoma.

[Noteable]

TCR sequencing is a biomarker that can be applied in requesting an Accelerated Approval.

[13X2413]

You continue to be positive and it's clear you're much smarter than I am on this subject matter.  Please explain why the market continues to turn up its nose on anything the company releases? This is like getting k*cked in the balls everyday. 

[Noteable]

13x just look in the mirror for your answer.

[13X2413]

Not quite the answer I was looking for. :)

[Noteable]

T cell receptor sequencing (TCR-seq) showed an expansion of new and pre-existing T-cell clones.

[Buckhenry]

SOS... different conference... hope Matt does another fireside chat.. makes me all gitty in that soft spot just thinking about it. 

[Noteable]

Should read : TCR clonality is a biomarker that can be applied in requesting an Accelerated Approval.

[fasttrack5]

The tumor objective response rate (ORR) is the assessment of the tumor burden (TB) after a given treatment in patients with solid tumors and has a long history. The ORR is undoubtedly an important parameter to demonstrate the efficacy of a treatment and it serves as a primary or secondary end-point in clinical trials.